TOE1

Across TCGA pan-cancer cohorts, TOE1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TOE1 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TOE1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TOE1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

OV, PDAC, and LSCC are the cancer types where TOE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Tertile	All	0.454	0.835	.015	16	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
LSCC	DFS	Median	II,III,IV	1.000	0.502	.038	4	view →
LUAD	DFS	Median	All	0.847	0.949	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TOE1–OV (DFS)

Open the OV breakdown →